Global Rheumatic Disorders Drugs Market Grow at (CAGR) of 4.46% to $80.04 billion in 2024

Global Rheumatic Disorders Drugs Market to 2024 research report covers key diseases of rheumatic disorders, market size, therapy area overview, etiology, Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation and key marketed products.

Pune, India - February 12, 2019 /MarketersMedia/ —

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry research report added to ReportsnReports online database.
The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

Get Discount on Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854866

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders market landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to Buy:
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the Rheumatic Disorder Drug Market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Direct Purchase of Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854866

Table of Contents:
1. Introduction
2. Key Marketed Products
3. Pipeline Landscape Assessment
4. Multi-scenario Market Forecast to 2024
5. Company Analysis and Positioning
6. Strategic Consolidations
7. Appendix

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854866-global-rheumatic-disorders-drugs-market-to-2024-increased-uptake-of-il-inhibitors-and-jak-inhibitors-to-drive-growth-as-tnf-inhibitors-face-patent-expiry.html

Source URL: https://marketersmedia.com/global-rheumatic-disorders-drugs-market-grow-at-cagr-of-446-to-8004-billion-in-2024/481750

Source: MarketersMedia

Release ID: 481750

Latest News

Malaysia climber at hospital after 2 days alone on Annapurna

Apr 26, 2019

KATHMANDU, Nepal — A Malaysian mountain climber was being treated in a hospital in Nepal's capital Friday after being stranded nearly two days alone near the summit of Annapurna. A helicopter crew searching for the missing climber on Thursday spotted Wui Kin Chin waving his hands at them, and rescuers brought him down to a lower camp. At the time of his rescue, Chin had been without an oxygen bottle, food and water for over 40 hours, said Mingma Sherpa, the head of Seven Summit Treks, which arranged his expedition. Chin was flown to the capital, Kathmandu, on Friday and...

Despite big plans, N. Korea's trains still go almost nowhere

Apr 26, 2019

TOKYO — North Korean leader Kim Jong Un's decision to take a train to his summit with President Vladimir Putin in Russia's far east hints at the potential of a much bigger dream long held by many in Asia: unimpeded travel by rail from the southern tip of the Korean Peninsula to Moscow and beyond. The economic benefits range from linking big, thriving markets and bolstering regional cooperation to slashing costs and travel durations. But with sanctions and distrust standing in the way, it could be a very long time before any trains working their way north from Seoul will...

NRA diminished from role played in 2016 election

Apr 26, 2019

WASHINGTON — The nation's largest gun rights organization played a pivotal role in President Donald Trump's victory in 2016. Three years later, the National Rifle Association is limping toward the next election divided and diminished. It's a reversal that has stunned longtime observers and that is raising questions about the one-time kingmaker's potential firepower heading into 2020 as Trump and Vice President Mike Pence prepare to headline the group's annual convention in Indianapolis on Friday. "I've never seen the NRA this vulnerable" said John Feinblatt, president of Everytown for Gun Safety, a nonprofit that advocates for gun control measures. In...

Putin: Belt and Road fits with Eurasian Economic Union goals

Apr 26, 2019

BEIJING — China's Belt and Road infrastructure initiative meshes perfectly with the goals of the Russian-led Eurasian Economic Union, Russian President Vladimir Putin said Friday. Putin's comments to a Belt and Road forum in Beijing may help alleviate concerns over potential tensions between China and Russia, given Beijing's rapidly expanding economic footprint in Central Asia, Moscow's traditional sphere of influence. Putin told some three-dozen leaders attending the conference that China's moves "fit perfectly into our plans." The Eurasian Economic Union groups Russia with Armenia, Belarus, Kazakhstan and Kyrgyzstan in a common market that seeks to remove barriers to the free...

Deutsche Bank earnings up in 1st quarter but revenues drop

Apr 26, 2019

BERLIN — Deutsche Bank says it saw its profit improve by 67 percent in the first quarter, though revenue dropped 9 percent as proceeds from trading declined sharply. Germany's biggest bank reported details of its January-March earnings on Friday, a day after it abandoned talks on a possible merger with German peer Commerzbank. The company said net profit was 201 million euros ($224 million), compared with 120 million euros a year earlier. Revenues dropped to 6.35 billion euros from 6.98 billion euros. The bank said revenues from fixed income sales and trading were off 19 percent at 1.5 billion euros,...

Search

Deck Biz is an intelligent platform providing international and regional business news updates. You won’t get these insights elsewhere other than Deck Biz.

Contact us: sales@deckbiz.com